Back to News & Events

Funding Opportunity for SBU Researchers: Development and Commercialization of Bio-Based Technologies for Human Health 

The Center for Biotechnology on behalf of the Long Island Bioscience Hub is pleased to announce a request for proposals for our two-tiered technology development & commercialization program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo).  More information can be found thru this link (or view on CfB web-page)… 

Review the full funding program overview and proposal guidelines

Stony Brook University faculty and postdoctoral associates, alone or in partnership with companies or CFB-appointed BioEntrepreneurs-in-Residence (BEIRs), are eligible to apply. In all instances, the faculty member or post-doctoral associate must serve as the principal investigator, and the project must be executed on the academic campus at Stony Brook University.

Application Deadline: March 7, 2024 no later than 5pm.

Interested applicants are strongly recommended to connect with the Center for Biotechnology team before writing a full proposal and submission.  
Please contact Phuong Nguyen, PhD, at the Center for Biotechnology: phuong.t.nguyen@stonybrook.edu.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4285
                    [post_author] => 4
                    [post_date] => 2023-09-11 12:13:16
                    [post_date_gmt] => 2023-09-11 16:13:16
                    [post_content] => 

Join Stony Brook University’s Intellectual Property Partners on Thursday, October 12, from 4:30 pm to 6 pm at the Charles B. Wang Center at Stony Brook University for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.”

The event will be hosted by Intellectual Property Partners (IPP), the SBU Chapter of the National Academy of Inventors (NAI), and the Manufacturing and Technology Resource Consortium (MTRC) and will be followed by a networking cocktail reception from 6 pm to 7 pm.

Moderated by Dr. James Hayward, President, CEO and Chairman of Applied DNA Sciences, panelists include:
– Adrian Howansky, PhD, Clinical Medical Physicist, Department of Radiology, Stony Brook University Hospital
– Doreen Swift, Senior Director, Embedded Software Engineering, IPS
– Michael R. Bielski, President, DevTech Partners
– Nariman Boyle, MD, Director, Ophthalmic Plastic Orbit and Reconstructive Surgery, Department of Ophthalmology, Renaissance School of Medicine, Stony Brook University
– Paul Schwartz, Director, Advanced Propulsion Technologies

This event is free and open to Stony Brook University attendees. Space is limited and registration is required. Register here to secure your spot.

For more information visit: https://www.stonybrook.edu/commcms/ipp/Events/Manufacturing.php

[post_title] => "Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing" 10/12/23 [post_excerpt] => Join Stony Brook University’s Intellectual Property Partners on October 12th for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.” [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bring-your-new-technology-innovations-to-life-through-prototyping-and-manufacturing-10-12-23 [to_ping] => [pinged] => [post_modified] => 2023-11-15 11:24:35 [post_modified_gmt] => 2023-11-15 16:24:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4285 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 1208 [post_author] => 3 [post_date] => 2014-07-17 13:24:02 [post_date_gmt] => 2014-07-17 13:24:02 [post_content] => Israel Kleinberg, DDS,PhD, DSc, Distinguished Professor in the Depart of Oral Biology and Pathology, at Stony Brook University, and his commercial partner Ortek Therapeutics, have launched BasicBites®, a chewable candy that is actually beneficial for your teeth. BasicBites? are designed to mimic saliva's profound and natural benefits. The science behind BasicBites, AlkaGen Technology™, was developed in part with support from the Center for Biotechnology. Read the full press release and more about the launch. More information on the product can be found on the BasicBites? website at www.basicbites.com. [post_title] => BasicBites™, Candy for Dental Health Launched [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => basicbites-candy-for-dental-health-launched [to_ping] => [pinged] => [post_modified] => 2016-03-21 21:56:53 [post_modified_gmt] => 2016-03-21 21:56:53 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1208 [menu_order] => 224 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2965 [post_author] => 4 [post_date] => 2018-03-08 15:43:23 [post_date_gmt] => 2018-03-08 15:43:23 [post_content] => SUSTAINED NANO SYSTEMS ACHIEVES POSITIVE IN-VITRO RESULTS ON LONG TERM SUSTAINED DELIVERY OF LATANAPROST FOR GLAUCOMA TREATMENT. New York, NY – March 6, 2018 (NEWSFRONT MEDIA). Sustained Nano Systems, LLC (“SNS”), a biopharmaceutical company utilizing its platform technology of bio-resorbable nano and microparticles for long term drug delivery, is pleased to announce positive results for the in-vitro presence of Latanaprost for the treatment of glaucoma over a duration of 159 days. Latanaprost, a prostaglandin analogue, is the #1 glaucoma drug in the world, with dosing of up to four eye drops every day for the remainder of a patient’s life. Latanaprost reduces elevated intraocular pressure in open-angle glaucoma or ocular hypertension. At the present time, there is no long-acting formulation for glaucoma, only multiple daily eyedrops. SNS LAT-LA (Latanaprost Long Acting) is designed to be administered by a single periocular injection with a duration of six months. “The potential for SNS LAT-LA to sustain deliver for six months, would fulfill an important unmet need in replacing the more burdensome and potentially less compliant regimen of daily eye drops,” said Dr. Barry Libin, CEO of SNS. LAT-LA will now undergo further studies to indicate its efficacy in the long term reduction of intra-ocular pressure. Glaucoma is the second leading cause of blindness in the world, in which abnormally high intraocular pressure may cause damage to the optic nerve, resulting in irreversible vision loss. In the U.S. alone, 2.7 million people suffer from glaucoma. According to IMS Health data, there were 34 million prescriptions and sales of over $2.7 billion of drugs administered by eye drops for the treatment of glaucoma in the U.S. in 2017, and global spending was over $6 billion. Compliance is the biggest problem with existing therapies for glaucoma, with more than 50% of patients on topical prostaglandin analogs not compliant within the first six months of treatment ABOUT SUSTAINED NANO SYSTEMS (SNS) SNS is a privately held biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions in ophthalmology, oncology and other areas. The Company’s research facility is located on the campus of Stony Brook University as part of the Long Island High Technology Incubator. The SNS platform is the result of a comprehensive research effort that allows for long term micro-dosing for the continuous release of drugs to targeted tissues as prescribed. The basis of the SNS pipeline is its patented technology that incorporates bio-resorbable nano and micro carriers to deliver sustained delivery of important therapeutics, including anti-inflammatories and monoclonal antibodies for immunotherapies in cancer, retinal disease, and other disease states. For further information, visit: www.sustainednanosystems.net Forward-Looking Statements SNS Disclosure Notice: This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward looking statements. Investors are cautioned that all forward looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company’s control. Investors are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law. Contact: Dr. Barry Libin  (516) 353‐7983, barlibin@gmail.com Media Relations: info@newsfrontmedia.com [post_title] => Sustained Nano Systems Reports Positive In-Vitro Results Glaucoma Treatment [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => open [post_password] => [post_name] => sustained-nano-systems-achieves-positive-in-vitro-results-on-long-term-sustained-delivery-of-latanaprost-for-glaucoma-treatment [to_ping] => [pinged] => [post_modified] => 2018-08-20 14:51:29 [post_modified_gmt] => 2018-08-20 14:51:29 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2965 [menu_order] => 123 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4074 [post_author] => 4 [post_date] => 2023-04-24 16:22:15 [post_date_gmt] => 2023-04-24 16:22:15 [post_content] =>

The Center for Biotechnology has announced the appointment of Dr. Louis A. Peña as Director of the new Program in Life Sciences Innovation and Entrepreneurship. Additionally, Dr. Peña has been appointed as Associate Professor of Practice in the Department of Biomedical Engineering and the College of Business at Stony Brook University.

The Professor of Practice will steward the University’s Advanced Graduate Certificate in Life Science Innovation and Entrepreneurship, which was established under Empire State Development’s Life Science Entrepreneur Development award, and further develop educational and experiential learning initiatives. The Director of the Program in Life Sciences Innovation and Entrepreneurship will build upon the Center’s efforts to synergize technology and business accelerator activities with opportunities for students to gain real-world technology commercialization experience.

Prior to joining the Center for Biotechnology and Stony Brook University, Dr. Peña held leadership positions in both industry and academia. He is experienced with startup and early stage companies. Commercializing scientific discoveries he made at Brookhaven National Laboratory, Dr. Peña co-developed a biotech startup that took a biomaterial from idea to clinical trials and acquisition. He later served as Chief Scientific Officer of a biopharma Contract Research Organization. Dr. Peña has also consulted for technology startups in bioagriculture, medical devices, medical imaging, and energy, supporting technology assessment, market assessment, and business strategy.

“We are excited to have Louis join the Center for Biotechnology and Stony Brook University to further our efforts of expanding entrepreneurial education in the life sciences” Diane Fabel, Director of Operations at the Center for Biotechnology said. She continued “His industry involvement, coupled with his academic experiences allow him to bring a unique perspective to the role and for students in our programs to benefit from his real-world experience.”

“I am very happy to join the team at the Center for Biotechnology and my colleagues at Stony Brook University. The Center has a great, established foundation of commercialization and education in this sector and I’m eager to further develop these unique and critical programs” Dr. Peña said. “Our goal is to bolster the life science commercialization knowledge of students graduating from New York universities. At one level, this will help entrepreneurs gain the mix of skills and expertise needed to successfully guide innovative life science startups along the path to commercial viability. At a broader level, this will help with the biotech workforce development of our region and state for those who may not want to start companies but want to understand the sector in great depth so they can secure well-paying and/or leadership positions in this sector.”

Download a PDF of the announcement here.

[post_title] => Dr. Louis A. Peña appointed Director, Program in Life Sciences Innovation and Entrepreneurship & Associate Professor of Practice [post_excerpt] => Dr. Peña will steward the University’s Advanced Graduate Certificate in Life Science Innovation and Entrepreneurship, and build upon the Center’s efforts to synergize technology and business accelerator activities with opportunities for students. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => dr-louis-a-pena-appointed-director-program-in-life-sciences-innovation-and-entrepreneurship-associate-professor-of-practice [to_ping] => [pinged] => [post_modified] => 2023-07-10 12:38:52 [post_modified_gmt] => 2023-07-10 16:38:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4074 [menu_order] => 3 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4285 [post_author] => 4 [post_date] => 2023-09-11 12:13:16 [post_date_gmt] => 2023-09-11 16:13:16 [post_content] =>

Join Stony Brook University’s Intellectual Property Partners on Thursday, October 12, from 4:30 pm to 6 pm at the Charles B. Wang Center at Stony Brook University for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.”

The event will be hosted by Intellectual Property Partners (IPP), the SBU Chapter of the National Academy of Inventors (NAI), and the Manufacturing and Technology Resource Consortium (MTRC) and will be followed by a networking cocktail reception from 6 pm to 7 pm.

Moderated by Dr. James Hayward, President, CEO and Chairman of Applied DNA Sciences, panelists include:
– Adrian Howansky, PhD, Clinical Medical Physicist, Department of Radiology, Stony Brook University Hospital
– Doreen Swift, Senior Director, Embedded Software Engineering, IPS
– Michael R. Bielski, President, DevTech Partners
– Nariman Boyle, MD, Director, Ophthalmic Plastic Orbit and Reconstructive Surgery, Department of Ophthalmology, Renaissance School of Medicine, Stony Brook University
– Paul Schwartz, Director, Advanced Propulsion Technologies

This event is free and open to Stony Brook University attendees. Space is limited and registration is required. Register here to secure your spot.

For more information visit: https://www.stonybrook.edu/commcms/ipp/Events/Manufacturing.php

[post_title] => "Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing" 10/12/23 [post_excerpt] => Join Stony Brook University’s Intellectual Property Partners on October 12th for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.” [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bring-your-new-technology-innovations-to-life-through-prototyping-and-manufacturing-10-12-23 [to_ping] => [pinged] => [post_modified] => 2023-11-15 11:24:35 [post_modified_gmt] => 2023-11-15 16:24:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4285 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 249 [max_num_pages] => 83 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

“Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing” 10/12/23

More Information

BasicBites™, Candy for Dental Health Launched

More Information

Sustained Nano Systems Reports Positive In-Vitro Results Glaucoma Treatment

More Information

Dr. Louis A. Peña appointed Director, Program in Life Sciences Innovation and Entrepreneurship & Associate Professor of Practice

More Information